Results 291 to 300 of about 47,580 (341)

Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Elranatamab, a bispecific antibody targeting B‐cell maturation antigen, is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). An exposure–safety analysis was conducted using the data from patients with RRMM across four clinical studies, MagnetisMM‐1, 2, 3, and 9 (NCT03269136, NCT04798586, NCT04649359, and NCT05014412)
Pooneh Soltantabar, Jennifer Hibma, Diane Wang, Umberto Conte, Anne Hickman, Mohamed Elmeliegy   +5 more
wiley   +1 more source

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. [PDF]

Blood Adv
Banerjee R, Mohan M, Rejeski K, Puliafito BR, Cirstea DD, Kaur G, Midha S, McCaughan GJ, Kumar NM, Mehra N, Bagal B, Raje NS.   +11 more
europepmc   +1 more source

Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

Journal of Extracellular Vesicles, Volume 15, Issue 1, January 2026.
Non‐invasive biomarkers are needed to further personalize EGFR tyrosine kinase inhibitor (EGFR TKI) osimertinib treatment in non‐small cell lung cancer (NSCLC) patients. By analysing the proteome of extracellular vesicles (EVs) isolated from an osimertinib resistant NSCLC cell line and from serum of patients given osimertinib in second line within the ...
Albano Cáceres‐Verschae, Petra Hååg, Sofia Joelsson, Per Hydbring, Bo Franzén, Ákos Végvári, Inger Johanne Z. Eide, Nupur Agarwal, Siddharth Sourabh Sahu, Fredrik Stridfeldt, Luigi De Petris, Apurba Dev, Simon Ekman, Odd Terje Brustugun, Rolf Lewensohn, Kristina Viktorsson   +15 more
wiley   +1 more source

A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. [PDF]

Nat Commun
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS.   +15 more
europepmc   +1 more source

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy

Hematological Oncology, Volume 44, Issue 1, January 2026.
Pier Luigi Zinzani, Giulia Dell’Omo, Letizia Fusco, Ilaria Peduto, Carlotta Galeone, Federica Cavallo, Giuseppe Gritti   +6 more
wiley   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment. [PDF]

Clin Transl Med
Li N, Li R, Ma Q, Zhang X, Ma W, Wang Y, Duan B, Yang K, Zhang D, Zhang J, Gu M, Wu Y, Sun J, Wang H, Li A, Chen F, Bai Y, Tian Y, Li X, Yan Y, Wang W, Zhang H, Wang Y.   +22 more
europepmc   +1 more source

Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 1, January 2026.
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li, Yuezhou Wu, Zhu'anzhen Zheng, Fengjin Zhou, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Bispecific antibody therapy-associated opportunistic infections: cytomegalovirus retinitis and chronic salmonellosis in a non-HIV patient. [PDF]

Haematologica
Cochran-Perez MR, Sharma P, Delisle JS, Schlesinger M, Rao H, Trias J, Keller M.   +6 more
europepmc   +1 more source

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source